- Home
- IMMX vs VYNE Comparison
IMMX vs VYNE Comparison
Compare IMMX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- VYNE
- Stock Information
- Founded
- IMMX 2014
- VYNE 2003
- Country
- IMMX United States
- VYNE United States
- Employees
- IMMX N/A
- VYNE N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- VYNE Health Care
- Exchange
- IMMX Nasdaq
- VYNE Nasdaq
- Market Cap
- IMMX 46.8M
- VYNE 41.9M
- IPO Year
- IMMX 2021
- VYNE 2018
- Fundamental
- Price
- IMMX $1.67
- VYNE $3.07
- Analyst Decision
- IMMX Strong Buy
- VYNE Strong Buy
- Analyst Count
- IMMX 1
- VYNE 2
- Target Price
- IMMX $7.00
- VYNE $6.88
- AVG Volume (30 Days)
- IMMX 89.1K
- VYNE 122.3K
- Earning Date
- IMMX 11-12-2024
- VYNE 11-07-2024
- Dividend Yield
- IMMX N/A
- VYNE N/A
- EPS Growth
- IMMX N/A
- VYNE N/A
- EPS
- IMMX N/A
- VYNE N/A
- Revenue
- IMMX N/A
- VYNE $493,000.00
- Revenue This Year
- IMMX N/A
- VYNE $32.31
- Revenue Next Year
- IMMX $200.00
- VYNE N/A
- P/E Ratio
- IMMX N/A
- VYNE N/A
- Revenue Growth
- IMMX N/A
- VYNE 39.27
- 52 Week Low
- IMMX $1.26
- VYNE $1.57
- 52 Week High
- IMMX $7.75
- VYNE $4.09
- Technical
- Relative Strength Index (RSI)
- IMMX 50.69
- VYNE 59.02
- Support Level
- IMMX $1.65
- VYNE $2.65
- Resistance Level
- IMMX $1.93
- VYNE $3.05
- Average True Range (ATR)
- IMMX 0.16
- VYNE 0.23
- MACD
- IMMX 0.01
- VYNE -0.05
- Stochastic Oscillator
- IMMX 42.55
- VYNE 34.57
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.